GSK: two Zantac-related claims settled out of court

(CercleFinance.com) - GSK announced on Wednesday that it had reached out-of-court settlements with two American plaintiffs, who blamed Zantac, a heartburn medication once marketed by the biopharmaceutical group, for causing their cancer.


The British laboratory specifies that these agreements, the terms of which have not been made public, were reached with John Russell, who attributed his bladder cancer to taking this gastric acidity tablet, and with Annette Hughes, who suffered from colorectal cancer.

In a brief press release, GSK stresses that the end of these two lawsuits will put an end to the proceedings that the two plaintiffs had brought before a Californian court.

The company, which does not admit liability in either case, points out that 16 epidemiological studies conducted since 2019 have shown no evidence that ranitidine, the scientific name of Zantac, increases the risk of cancer.

GSK promises to defend itself vigorously and to approach the litigation in the best interests of the company and its shareholders.

On the London Stock Exchange, GSK shares were down 0.7% after this announcement.

Copyright (c) 2024 CercleFinance.com. All rights reserved.